Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Esophageal Neoplasms 3Sarcoma 2Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Solid Cancer 1Sarcoma, Synovial 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasm Metastasis 1Metastatic Gastric Adenocarcinoma 1Locally Advanced Unresectable Gastric Adenocarcinoma 1Liver Neoplasms 1Desmoplastic Small Round Cell Tumor 1Carcinoma, Renal Cell 1Carcinoma 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

pembrolizumab 2atezolizumab 2trastuzumab deruxtecan 1toripalimab 1pertuzumab 1durvalumab 1Trastuzumab 1S-Adenosylmethionine 1Ramucirumab 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Fluorouracil 1Etoposide 1Cetuximab 1Carboplatin 1Capecitabine 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Solid Cancer × Ramucirumab × Clear all
NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

FBD Biologics Limited

Phase 1/2 Active not recruiting
500 enrolled

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡